Drug Approval | August 06, 2021
India’s gets its first bio-bank for heart failure research
Centre at Sree Chitra Tirunal Institute for Medical Sciences and Technology
Centre at Sree Chitra Tirunal Institute for Medical Sciences and Technology
The company posted net loss of Rs.56.69 crores for the period ended June 30, 2020.
As of 2025, the new Translational Science Center will offer room for more than 500 scientists, who will conduct research in a wide variety of fields ranging from the identification of disease biomarkers to the development of targeted therapies
Growing R&D budgets of global pharmaceutical companies is the opportunity that Veeda and Bioneeds expect to capitalise on.
The company has posted net loss of Rs. 99.54 crores for the period ended March 31, 2020
The company will review FDA's response and decide on appropriate next steps soon.
The company posted net loss of Rs. 55.51 crores for the period ended December 31, 2019.
As competition intensifies in the obesity treatment market, a next-generation therapy may be in development.
Approval makes it the first and only therapy in the EU indicated for both acute and chronic hepatitis C, supported by Phase 3 data
The research underscores growing concern that the intersection of neurodevelopmental conditions and social disadvantage can significantly compound health risks across the life course
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
